In the period from 2018 to 2023, 28 percent of clinical drug trials started during these years were in the field of oncology, whereas a combined 13 percent of trials started were for infectious diseases (therapeutic and immunization). This statistic depicts the proportion of clinical trials started worldwide from 2018 to 2023, by key therapeutic area.

The probability that a cancer drug will make it from phase I to final approval stood at some 2.4 percent, according to a study published in March 2020. The data is based on clinical success rate models from 2014, 2016, and 2019. Once a cancer drug made it into phase III, the chances to make it to final approval increased to 35.5 percent.

This statistic shows the number of clinical trial participants in the U.S. compared to the rest of the world in 2015-2019, by therapeutic area. In the oncology and hematology area, there were some 9,200 clinical trial participants in the United States whereas there were 25,700 participants in the rest of the world.

Healthcare Contract Research Outsourcing Market size was valued at USD 43.22 Billion in 2024 and is projected to reach USD 75.66 Billion by 2031, growing at a CAGR of 7.25% during the forecast period 2024-2031.

Global Healthcare Contract Research Outsourcing Market Drivers

The market drivers for the Healthcare Contract Research Outsourcing Market can be influenced by various factors. These may include:

Increasing Research and Clinical Trial Involvement: There has been an increase in research and development activity in the biotechnology and pharmaceutical sectors, which has raised the need for clinical trial outsourcing. Healthcare CROs are essential to the success of these trials and the expansion of the market as a whole.

Time savings and cost effectiveness: Drug development can proceed more quickly and with lower operating expenses for pharmaceutical and biotech businesses that outsource their clinical research operations to CROs. CROs frequently have specialized infrastructure and knowledge, which boosts productivity and shortens turnaround times.

Global Clinical Trials Industry: The increasing number of clinical trials being done in different parts of the world has led to the demand for CROs with local knowledge who can manage a variety of trial populations and negotiate regulatory environments.

The intricacy of the drug development process: With developments in personalized medicine, genetics, and medical research, the process of developing new drugs has grown increasingly intricate. To take use of CROs’ specialized resources and skills, pharmaceutical corporations outsource different parts of clinical trials to them.

Strategic Emphasis on Fundamental Skills: Many biotech and pharmaceutical businesses would rather outsource their clinical research operations to specialized CROs and concentrate on their core skills, such marketing and drug discovery. They are able to distribute resources more skillfully as a result.

Clinical trial cost per patient was highest in the blood therapeutic area, ranging between 200 thousand and 422 thousand U.S. dollars with a median of some 311 thousand dollars. This statistic shows the estimated per patient trial costs by therapeutic area, for the period 2015-2017.

The Report Covers Pediatric Clinical Trials Market Research and the Market is Segmented by Phase (Phase I, Phase II, Phase III, and Phase IV), Study Design (Treatment Studies and Observational Studies), Therapeutic Area (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes, and Other Therapeutic Areas) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Provides the Value (in USD Million) for the Above-Mentioned Segments.

The rare disease clinical trials market size is projected to be valued at US$ 12,566.14 million in 2023 and is expected to rise to US$ 31,715.25 million by 2033. The sales of rare disease clinical trials are expected to record a significant CAGR of 9.7% during the forecast period.

Scope of the Report

Dermatology CRO Market size was valued at USD 4.91 Billion in 2024 and is projected to reach USD 8.32 Billion by 2031, growing at a CAGR of 6.80% during the forecast period 2024-2031.

Global Dermatology CRO Market Drivers

The market drivers for the Dermatology CRO Market can be influenced by various factors. These may include:

Growing Prevalence of Skin Disorders: The need for dermatological services, including clinical trials, is being driven by the increased prevalence of a number of skin conditions, including eczema, psoriasis, acne, and skin cancer.
Growing Need for Cosmetic Procedures: As people attention turns more and more to appearances, there is a greater need for cosmetic dermatological treatments. This, in turn, raises the question of whether clinical research is necessary in this area.
Developments in Dermatological medicines: The demand for clinical trials to evaluate the safety and efficacy of dermatological medicines, such as biologics, targeted therapies, and personalized medicine, is growing.
Growing R&D Investments: More clinical trials and partnerships with CROs are being conducted as a result of pharmaceutical and biotechnology companies’ growing R&D expenditures in dermatology.
Regulatory encourage for Clinical Research: The dermatology CRO industry is expanding as a result of favorable regulatory policies and programs that encourage clinical research. Examples of these include accelerated approval processes and incentives for research on rare diseases.
Technological Advancements in Clinical studies: More sponsors are choosing to undertake dermatology studies as a result of the increased efficiency, lower costs, and increased use of technology like as wearables, telemedicine, and electronic data capture (EDC).
Increasing Trend of R&D Activity Outsourcing: As sponsors may concentrate on their core skills and cut research expenses, there is an increasing trend of outsourcing R&D operations, including clinical trials, to CROs.

Clinical Trial Management Software Market size was valued at USD 1009.73 Million in 2024 and is projected to reach USD 2310.23 Million by 2031, growing at a CAGR of 10.90% from 2024 to 2031.

Clinical Trial Management Software Market Drivers

The Escalating Intricacy of Clinical Trials: comprising more substantial study populations, varied geographical locations, and intricate study designs—motivates the demand for advanced CTMS solutions that can effectively optimize and oversee trial procedures.

Life Sciences R&D Investments in Ascent: The expansion of clinical trial activities is facilitated by pharmaceutical, biotechnology, and medical device companies’ ongoing investments in research and development (R&D) within the life sciences. By assisting in the management and optimization of these trials, CTMS software increases their appeal to sponsors.

Strict Regulatory Obligations: In order to ensure transparency in clinical trial operations and adhere to regulatory standards, organizations are compelled to implement CTMS solutions. These software systems ensure patient safety and data integrity by aiding in the maintenance of compliance with numerous regulatory bodies.

Emphasis on Patient-Centric Trials: The clinical trial industry is currently transitioning towards patient-centric approaches, which prioritize patient experience and engagement. As a result, there is a growing need for CTMS solutions that can streamline patient recruitment, retention, and monitoring processes.

The clinical trial market is estimated to be US$ 120.97 billion in 2024. From 2024 to 2034, the market is expected to progress at a solid clip, registering a CAGR of 4.3%. By 2034, the clinical trial market is anticipated to have reached a value of US$ 184.61 billion.

Category-wise Outlook

Country-Wise Analysis

The AI in Clinical Trials Market Report is Segmented by Component Type (Software and Services), Therapeutic Area (Oncology, Cardiovascular Diseases, Metabolic Diseases, Infectious Diseases, and Other Therapeutic Areas), End User (Pharmaceutical and Biotechnological Companies, Contract Research Organizations, and Research and Academic Institutes), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Market Sizes and Forecasts in Value Terms (USD) for all the Above Segments.

CRO Services Market size is valued at USD 67.16 Billion in 2024 and is anticipated to reach USD 160.9 Billion by 2031, growing at a CAGR of 11.54% from 2024 to 2031

Global Contract Research Organizations Services Market Drivers

Growing Need for Novel Drugs: The pharmaceutical business is being driven to provide novel and inventive therapies due to the increasing prevalence of chronic illnesses including diabetes, cancer, and cardiovascular disorders. Clinical trials, a primary service provided by CROs, become more necessary as a result.

Patent Expirations: When a drug’s patent expires, generic substitutes and the creation of new drugs are given a chance. This increases competitiveness and calls for quicker drug development schedules, which CROs can handle with ease.

Globalization of Clinical studies: Because of things like cheaper prices and bigger patient pools, pharmaceutical corporations are performing more and more clinical studies in developing nations. CROs with a global reach and regulatory landscape navigation knowledge are attractive partners.

This statistic shows the total per-study costs by clinical trial phase and therapeutic area as of 2014, in million U.S. dollars. The clinical trial phase IV for studies of the respiratory system was the most expensive phase, with a total per-study cost of nearly 73 million U.S. dollars.

Snapshot img

Clinical Trial Supplies Market Size 2024-2028

The global clinical trial supplies market size is estimated to grow by USD 1.31 billion, at a CAGR of 8.65% between 2023 and 2028.

Biopharma is experiencing significant growth, driven by several key factors. Firstly, there is a rise in the demand for innovative biopharmaceutical products, fueled by advancements in medical research and an increasing focus on personalized medicine. Additionally, government initiatives aimed at promoting clinical research further stimulate industry expansion, providing funding and support for research and development activities and clinical trial support services.
Moreover, the regulation of clinical trials in regional markets ensures compliance with safety and ethical standards, fostering trust and confidence in biopharmaceutical products among healthcare professionals and consumers. These interconnected trends underscore the dynamic landscape of the biopharmaceutical industry, where collaboration between government agencies, research institutions, and industry stakeholders drives innovation and advances healthcare outcomes. As regulatory frameworks evolve and investment in research increases, the market for biopharmaceuticals is poised for continued growth, offering opportunities for improved treatments and medical breakthroughs in various therapeutic areas.

What will be the Size of the Clinical Trial Supplies Market During the Forecast Period?

To learn more about this market report, Download Report Sample

The global clinical trial supply market is experiencing a period of rapid evolution, driven by a combination of factors, including increasing complexity of clinical trials, advancements in technology, and growing demand for clinical research services. Key trends shaping the industry include a shift towards outsourcing of clinical trial supply chain activities, the growing importance of data management and analytics, and a focus on risk mitigation and continuity planning. As clinical trials become more complex and global in scope, there is a rising demand for specialized clinical trial supply services, including sourcing, logistics, and storage of clinical trial materials. Clinical trial supply forecasting has become a crucial aspect of this market, allowing for more accurate predictions in terms of demand, inventory management, and distribution to avoid costly delays and shortages.
Biopharmaceutical companies are increasingly seeking efficient clinical trial supply management strategies to ensure timely delivery of biological drugs to clinical sites worldwide. The clinical trial supplies industry plays a pivotal role in meeting these needs by ensuring that the required materials are available when and where they are needed, with a focus on minimizing waste and optimizing inventory levels. Supply chain management in clinical trials is becoming more sophisticated, driven by the increasing need to manage and coordinate resources across different regions and time zones. Additionally, the growing emphasis on biological drugs in clinical research has led to new challenges in sourcing and transporting temperature-sensitive materials.
The Clinical Trial Supplies Market is evolving with the increasing demand for regulatory-compliant logistics and cold chain distribution to ensure the safe delivery of trial materials. Comparator drug sourcing and direct-to-patient shipments are becoming more common, supported by decentralized trial support systems. Real-time tracking solutions and digital supply management are enhancing transparency and efficiency across the supply chain. GMP-certified packaging and temperature-controlled storage ensure the integrity of biologics trial supplies. Adaptive trial supply strategies, just-in-time inventory, and on-demand labeling solutions are optimizing resource allocation. Blockchain traceability further improves supply chain security, while decentralized models and advanced logistics capabilities continue to shape the future of clinical trials.

How is the Clinical Trial Supplies Market Segmented?

The clinical trial supplies market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

End-user

  Pharmaceutical industry
  Biologics industry
  Medical device industry


Type

  Phase III
  Phase II
  Phase IV and BE/BA studies
  Phase I


Service

  Manufacturing
  Packaging and Labeling
  Storage and Distribution
  Comparator Sourcing
  Ancillary Supplies
  Others


Therapeutic Area

  Oncology
  Cardiovascular Diseases
  Neurology
  Infectious Diseases
  Metabolic Disorders
  Others


Distribution Channel

  Direct-to-Site
  Depot-to-Site
  Others


Geography

  North America

    US
    Canada
    Mexico


  Europe

    Germany
    UK
    France

Language requirements in clinical trials by therapeutic area.

In 2023, 41 percent of clinical drug trials for oncology were in phase II and 14 percent of trials were in phase III. This statistic shows the share of clinical drug trials in the top five therapeutic areas worldwide in 2023, by trial phase.

The Contract Research Organization (CRO) Solutions market is experiencing robust growth, driven by the increasing demand for outsourced clinical research services by pharmaceutical and biotechnology companies. This surge is fueled by several factors, including the rising complexity of drug development, the need for accelerated timelines, and the cost-effectiveness of outsourcing non-core functions. The market size in 2025 is estimated at $50 billion, exhibiting a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033. This projection reflects the continued expansion of clinical trials, particularly in emerging therapeutic areas like oncology, immunology, and cell therapy, which necessitate specialized CRO services. Key segments like early-phase development and laboratory services are expected to witness above-average growth, driven by the increasing adoption of innovative technologies and advanced analytics in drug discovery and development. Geographical expansion, particularly in developing regions like Asia-Pacific, further contributes to market expansion. Leading CROs are strategically investing in expanding their service portfolios, enhancing technological capabilities, and forging strategic partnerships to capitalize on the growing market opportunities. The competitive landscape is marked by the presence of both large multinational corporations and specialized niche players. Consolidation and acquisitions are expected to remain significant trends, as larger players seek to broaden their service offerings and geographic reach. Regulatory changes and evolving ethical considerations within the clinical research landscape present both challenges and opportunities for CROs, requiring adaptation and strategic planning to ensure sustained growth. Despite potential restraints such as pricing pressures and increasing competition, the overall outlook for the CRO market remains positive, driven by the persistent demand for efficient and cost-effective drug development solutions.

Clinical Trial Supplies Market Research Analysis Report by Service (Manufacturing, Packaging, Logistics), by Phase (Phase1, Phase2, Phase3, Phase4), By Type (Small Molecules, Biologics), by Therapeutic Areas (Oncology, CVD, Infectious, Immunology) by End User (Pharma, Biotech, CRO’s)